Clinical Trials Logo

Clinical Trial Summary

STUDY JUSTIFICATION

1. Scientific evidence of the usefulness of corticosteroid use for infectious diseases: Corticosteroids along with antibiotic use improve survival in some infectious processes provide long term benefits and improve symptoms in many others.

2. Clinical Observation: the investigators observed that patients with parapneumonic pleural effusion and associated bronchospasm who were treated with corticosteroids for their bronchospasm, evolved to healing before patients who were not treated with corticosteroids (average admission days 10 vs. 17).

3. Rationale: the anti-inflammatory effect has been the rationale for the use of dexamethasone as an inhibitor of the inflammatory response observed after the first dose of parenteral antibiotic in bacterial meningitis. A similar effect is likely to occur in pneumonia with pleural effusion. It can be therefore hypothesized that Dexamethasone could inhibit an excessive inflammatory response by mesothelial and inflammatory cells during the early phases of parapneumonic empyema, reducing its severity and hence its complications.

OBJECTIVES

1. Principal: to investigate if dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic therapy reduces time to resolution of parapneumonic pleural effusion.

2. Secondary:

2.1. Evaluate the effect of dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic therapy on the development of complications during pleural effusion episode.

2.2. Evaluate the incidence of severe and non severe adverse events associated with the new treatment versus standard therapy.

METHODS

1. Study design: exploratory (pilot), randomized, double blinded, placebo controlled, parallel stratified design, multicentric.

2. Participating Hospitals (n=56, 7 patients per center):

- Hospital Infanta Sofía (S. Sebastián de los Reyes, Madrid).

- Hospital Universitario de Getafe

- Hospital Universitario Ramón y Cajal, Madrid.

- Hospital Universitario Materno-Infantil Carlos Haya, Málaga.

- Hospital Infantil La Paz, Madrid.

- Hospital U. Gregorio Marañón

- Hospital U. Príncipe de Asturias

- Hospital Virgen de la Salud, Toledo

3. Endpoints:

3.1. Primary: time to resolution. 3.2. Secondary endpoints:

1. Effectiveness: number of children with complications.

2. Safety (expected number: none). i) Hyperglycemia ii) Signs of gastrointestinal bleeding iii) Need of transfusion iv) Oropharyngeal Candidiasis v) Allergic reaction vi) Other adverse reactions described in the Medication Guide.

4. Treatment arms:

3.1. Control (0)

- Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.

- Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present.

- Ranitidine 5 mg/kg IV, q.d. for 2 days.

- Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.

3.2. Study treatment: (1)

- dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.

- Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present

- Ranitidine 5 mg/kg IV, q.d. for 2 days

- Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.

4. INCLUSION CRITERIA

- Patients between 1 and 14 year old.

- Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and radiological consolidation.

- Evidence of pleural effusion.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01261546
Study type Interventional
Source Hospital Infanta Sofia
Contact
Status Completed
Phase Phase 2
Start date December 2010
Completion date May 2015

See also
  Status Clinical Trial Phase
Recruiting NCT00103766 - Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion N/A
Completed NCT01178580 - Procoagulant Activity in Patients With Community Acquired Pneumonia, Pleural Effusion and Empyema N/A
Recruiting NCT00313066 - Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Phase 4
Completed NCT03468933 - Fibrinolysis Compared to Thoracoscopy for Pleural Infection Phase 4
Completed NCT03167723 - Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions N/A
Not yet recruiting NCT06235359 - Is Intercostal Tube Enough in Management of Empyema N/A
Completed NCT00323531 - Thoracoscopy Versus Fibrinolysis in Children With Empyema Phase 2/Phase 3
Not yet recruiting NCT03859206 - Medical Thoracoscopy Versus Tube Thoracostomy in Management of Empyema . N/A
Recruiting NCT01625247 - Drainage is Not Necessary Procedure After Laparoscopic Cholecystectomy Due to Severe Acute Cholecystitis Phase 3
Completed NCT00798278 - Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood Phase 3
Not yet recruiting NCT04695275 - Clinical Feature and Microbiology Characteristics of Empyema in Children
Recruiting NCT05620329 - UNC Pleural Fluid Registry
Withdrawn NCT01862458 - Empyema Treated With tPA & DNAse Phase 3
Completed NCT02446782 - Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy Phase 4
Completed NCT02014077 - VATS ( Video-Assisted Thoracoscopy) Compared to Reinsertion of a Thoracostomy Tube for Persistent Haemothorax N/A
Terminated NCT01287013 - Comparing Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures N/A
Recruiting NCT04193241 - Suturing With U-Technique Versus Un-Reapproximated Wound Edges During Removal of Closed Thoracostomy Tube Drain N/A
Not yet recruiting NCT06132997 - Medical Thoracoscopy in Treatment Outcomes of Empyema Management N/A
Completed NCT04350502 - Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections N/A
Completed NCT01522885 - KatGuide Method Versus Conventional Method at Insertion of Chest Tube Phase 3